Evidence map›Paper›PMID 30642080›Full record

ArticleInternational journal of molecular sciences2019

Ginsenoside Rb1 Blocks Ritonavir-Induced Oxidative Stress and eNOS Downregulation through Activation of Estrogen Receptor-Beta and Upregulation of SOD in Human Endothelial Cells.

Jian-Ming Lü, Jun Jiang, Md Saha Jamaluddin, Zhengdong Liang, Qizhi Yao, Changyi Chen

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Oxidative medicine and cellular longevity · 2023
    Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jian-Ming LüMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. jian-ming.lu@bcm.edu.
Jun JiangMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. Jiangjun_64@163.com.
Md Saha JamaluddinMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. mdsjam@gmail.com.
Zhengdong LiangMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. zhendonl@bcm.edu.
Qizhi YaoMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. qizhiyao@bcm.edu.
Changyi ChenMichael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA. jchen@bcm.edu.
Baylor College of Medicine · USMichael E. DeBakey VA Medical Center · US

Funding

National Institutes of Health R01 HL083471National Institutes of Health T32HL083774
6 · The paper itself

Abstract

We have previously shown that ritonavir (RTV), a highly active anti-retroviral therapy (HAART) drug, can cause endothelial dysfunction through oxidative stress. Several antioxidants including ginsenoside Rb1, a compound with antioxidant effect, can effectively block this side effect of RTV in endothelial cells. In the current study, we explored a mechanism by which ginsenoside Rb1 could protect these cells via binding of estrogen receptors (ERs). We found that several human endothelial cell lines differentially expressed ER-β and had very low levels of ER-α. RTV treatment significantly increased the production of reactive oxygen species (ROS) and decreased the expression of endothelial nitric oxidase synthase (eNOS) and superoxide dismutase (SOD) in HUVECs, while Rb1 effectively blocked these effects of RTV. These effects of Rb1 were effectively inhibited by silencing ER-β, indicating that ginsenoside Rb1 requires ER-β for its antioxidant activity in inhibiting the deleterious effect of RTV in human endothelial cells. Furthermore, Rb1 specifically activated ER-β transactivation activity by ER-β luciferase reporter assay. Rb1 competitively bound to ER-β, which was determined by the high sensitive fluorescent polarization assay.

Indexed as

Cell LineDown-RegulationEndothelial CellsEstrogen Receptor betaGinsenosidesHumansHuman Umbilical Vein Endothelial CellsNitric Oxide Synthase Type IIIOxidative StressReactive Oxygen SpeciesRitonavirSuperoxide DismutaseTranscriptional ActivationUp-RegulationESR2 protein, humanEstrogen Receptor betaginsenoside Rb1GinsenosidesNitric Oxide Synthase Type IIINOS3 protein, humanReactive Oxygen SpeciesRitonavirSuperoxide Dismutaseendothelial dysfunctionendothelial nitric oxidase synthaseestrogen receptorginsenoside Rb1oxidative stressritonavirsuperoxide dismutase

Identifiers

PMID30642080
PMCPMC6358897
OpenAlexW2910658653

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.